2-DG is under clinical development by NeuroGenomeX and currently in Phase II for Epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 2-DG’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

2-DG overview

2-DG (2-deoxy-D-glucose) is under development for the treatment of refractory epilepsy. It is a chemical analogue of glucose molecule which has the 2-hydroxyl group replaced by hydrogen so that it cannot undergo further glycolysis via phosphorylation by hexokinase. It is administered through oral route.

It was also under development for traumatic brain injury.

For a complete picture of 2-DG’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.